Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has announced that its t:slim X2 insulin pump, equipped with Control-IQ automated insulin delivery technology, is now approved for use with Eli Lilly’s Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU).
“Recent clinical studies have shown high satisfaction and quality of life benefits when using Lyumjev with Control-IQ technology,” said Jordan Pinsker, MD, Chief Medical Officer at Tandem Diabetes Care. “Ultra-rapid acting insulin is favored by many people with diabetes due to its quick response time. We are proud to offer Lyumjev compatibility with our t:slim X2 pump as part of an automated insulin delivery system in the EU, providing our customers with greater flexibility.”
Lyumjev received authorization for use in insulin pumps in the EU in 2020, but pump manufacturers must conduct extensive testing to confirm compatibility with specific insulin pumps and AID systems. Tandem and Lilly collaborated on the clinical trial demonstrating the benefits of Lyumjev with Control-IQ technology. The companies are also working to secure compatibility for the t:slim X2 pump in other regions and for the Tandem Mobi pump.
For more information, please see the Lyumjev Full Prescribing Information and Patient Prescribing Information. Additional details can be found on the European Medicines Agency (EMA) website.
The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, as well as Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in Canada and selected EU countries.
About Tandem Diabetes Care
Tandem Diabetes Care is a global leader in insulin delivery and diabetes technology, dedicated to manufacturing advanced automated insulin delivery systems that alleviate the challenges of diabetes management. The company’s portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California.
